Medical Patent News RSS Feed - Medical Patent News

Quest Diagnostics, Myriad Genetics reach agreement to end BRCA gene-patent litigation

Quest Diagnostics, Myriad Genetics reach agreement to end BRCA gene-patent litigation

Quest Diagnostics, the world's leading provider of diagnostic information services, today announced that it and Myriad Genetics Inc. have reached an agreement that ends their BRCA gene-patent litigation. [More]
VG Life Sciences issues patent relating to treatment of IBD through CLIP-inducing agent

VG Life Sciences issues patent relating to treatment of IBD through CLIP-inducing agent

VG Life Sciences, (VGLS), a biotechnology company developing therapies for autoimmune and infectious diseases, today announced the U.S. Patent and Trademark Office (USPTO) has issued U.S. Patent No. 8906846, covering a method of treating inflammatory bowel disease (IBD) through the administration of a CLIP-inducing agent. [More]
Altos Therapeutics announces issuance of Mexican patent covering dopamine D2/D3 drug candidates

Altos Therapeutics announces issuance of Mexican patent covering dopamine D2/D3 drug candidates

Altos Therapeutics, LLC announced today that the Mexican Institute of Industrial Property has issued Patent Number 323020 titled, "D2 Antagonists, Methods of Synthesis and Methods of Use". The patent broadly and specifically covers the company's dopamine D2/D3 drug candidates, their pharmaceutical compositions, and their use to treat a number of important gastrointestinal conditions in humans, such as gastroparesis. [More]
Study finds difference between results from IHC and quantitative molecular techniques

Study finds difference between results from IHC and quantitative molecular techniques

The cause of type 1 diabetes remains unknown. Several studies using immunohistochemistry (IHC) have independently reported hyperexpression of human leukocyte antigen (HLA) class I on pancreatic islet cells in young patients with recent-onset type 1 diabetes. Investigators have therefore suggested that HLA hyperexpression may be an important first step in the development of type 1 diabetes. [More]
LCS Therapeutics collaborates to commercialize patent on method to treat binge eating disorder

LCS Therapeutics collaborates to commercialize patent on method to treat binge eating disorder

LCS Therapeutics announced today that it has entered into a strategic collaboration with Lucerne Biosciences, LLC to commercialize U.S. Patent No. 8,318,813 entitled "Method of Treating Binge Eating Disorder." [More]
BMC Medical wins patent infringement lawsuit against ResMed

BMC Medical wins patent infringement lawsuit against ResMed

The International Trade Commission (ITC) issued its final decision in the case brought by ResMed (RMD) against BMC Medical. [More]
Patent recognizes peptide that reduces tissue damage

Patent recognizes peptide that reduces tissue damage

A Kansas State University research team has received a patent for its use of a peptide that has been shown to prevent or reduce damage to intestinal tissue. [More]
Elegant Medical to receive patent for groundbreaking Stethos electronic stethoscope

Elegant Medical to receive patent for groundbreaking Stethos electronic stethoscope

Elegant Medical LLC today announced it will receive an issued patent from the US Patent and Trademark Office for its groundbreaking Stethos electronic stethoscope, the most significant advancement to the stethoscope in half a century. [More]
GlySure awarded three U.S. patents for proprietary calibration technique, sensor membrane

GlySure awarded three U.S. patents for proprietary calibration technique, sensor membrane

GlySure Limited, developer of in-hospital continuous blood glucose monitoring (CBGM) systems, announced today that it has been awarded three U.S. patents covering the company's core proprietary calibration technique and sensor membrane. [More]
Kansas State University awarded patent for a series of synthetic compounds

Kansas State University awarded patent for a series of synthetic compounds

A patent has been issued for a series of synthetic compounds developed at Kansas State University that have applications for treating cancer and other diseases that affect cell communication. [More]
Study shows how exosomes secreted by tumor cells promote tumor growth

Study shows how exosomes secreted by tumor cells promote tumor growth

Researchers at the Bellvitge Biomedical Research Institute of Bellvitge, the Catalan Institute of Oncology and the University Hospital of Bellvitge have participated in an international study published in the journal Cancer Cell that describes how exosomes secreted by tumor cells contain protein and microRNA molecules capable of transform neighboring cells into tumoral cells promoting tumor growth. [More]
Special issue of Technology and Innovation includes articles from Patents for Humanity winners

Special issue of Technology and Innovation includes articles from Patents for Humanity winners

The current special issue of Technology and Innovation, is devoted to patents that benefit people around the world who live with limited resources, in challenging environments, and are in need of better access to basic needs and improved standards of living, health and infrastructure. [More]
Anti-cancer nanomedicines with smaller sizes exhibit enhanced performance in vivo, show studies

Anti-cancer nanomedicines with smaller sizes exhibit enhanced performance in vivo, show studies

Nanomedicines consisting of nanoparticles for targeted drug delivery to specific tissues and cells offer new solutions for cancer diagnosis and therapy. [More]
Amgen files lawsuit against Regeneron, Sanofi to prevent infringing manufacture of alirocumab

Amgen files lawsuit against Regeneron, Sanofi to prevent infringing manufacture of alirocumab

Amgen today announced that it filed a lawsuit in the United States (U.S.) District Court of Delaware against Sanofi, Aventisub LLC, formerly doing business as Aventis Pharmaceuticals Inc. (collectively "Sanofi"), and Regeneron Pharmaceuticals, Inc. ("Regeneron") for patent infringement of U.S. Patent Numbers 8,563,698, 8,829,165, and 8,859,741. [More]
Actavis seeks FDA approval to market generic version of Quillivant XR

Actavis seeks FDA approval to market generic version of Quillivant XR

Actavis plc today confirmed that it has filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration seeking approval to market Methylphenidate Hydrochloride for Extended-release Oral Suspension, 5 mg/mL. Actavis' ANDA product is a generic version of Pfizer and Tris Pharma's Quillivant XR®, which is a central nervous system stimulant indicated for the treatment of Attention Deficit Hyperactivity Disorder. [More]
Eye Co receives patent for new class of eye disease drugs

Eye Co receives patent for new class of eye disease drugs

Australian ocular technology company Eye Co Pty Ltd has achieved a key commercial milestone, with a patent granted protecting its new class of eye disease drugs throughout the high value European market. [More]
BGI issued patent for non-invasive prenatal genetic test technology

BGI issued patent for non-invasive prenatal genetic test technology

The European Patent Office has issued patent number EP2561103B1 for invention to BGI for its independently researched non-invasive prenatal genetic test (NIPT) technology. This technology has been developed by BGI in connection with the provision of its market leading NIPT, the NIFTY test. [More]
International Biophysics files patent protection for revolutionary AffloVest

International Biophysics files patent protection for revolutionary AffloVest

International Biophysics Corporation of Austin, Texas announces its filing of U.S. patent protection for its revolutionary AffloVest. The company has also recently confirmed exclusive ownership rights concerning the manufacture, sale and distribution of the AffloVest in its markets. [More]
TGen, NAU awarded patent for genomics-based test to detect H1N1 pandemic flu strain

TGen, NAU awarded patent for genomics-based test to detect H1N1 pandemic flu strain

The federal government has awarded a patent to the Translational Genomics Research Institute and Northern Arizona University for a test that can detect — and assist in the treatment of — the H1N1 pandemic flu strain. [More]
LLNL scientists issued patent for producing antimicrobial compounds to fight superbugs

LLNL scientists issued patent for producing antimicrobial compounds to fight superbugs

Superbugs, antibiotic-resistant bacteria, have been on the rise since antibiotics were first introduced 80 years ago. That's because these germ-fighting agents have lost their punch from being overprescribed and misused, allowing bacteria pathogens to develop immunities against them. [More]
Advertisement
Advertisement